LEADER 03829nam  2200697Ia 450 
001 9910953579403321
005 20251017110106.0
010   $a9786612083389
010   $a9780309181433
010   $a0309181437
010   $a9781282083387
010   $a1282083384
010   $a9780309550123
010   $a0309550122
035   $a(CKB)1000000000030479
035   $a(EBL)3377982
035   $a(SSID)ssj0000237582
035   $a(PQKBManifestationID)11188329
035   $a(PQKBTitleCode)TC0000237582
035   $a(PQKBWorkID)10191597
035   $a(PQKB)11472571
035   $a(MiAaPQ)EBC3377982
035   $a(Au-PeEL)EBL3377982
035   $a(CaPaEBR)ebr10087007
035   $a(CaONFJC)MIL208338
035   $a(OCoLC)923274892
035   $a(Perlego)4734697
035   $a(DNLM)1257684
035   $a(BIP)12806873
035   $a(EXLCZ)991000000000030479
100   $a20050630d2005      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aReview of the HIVNET 012 perinatal HIV prevention study /$fCommittee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$dc2005
215   $a1 online resource (149 p.)
300   $aDescription based upon print version of record.
311 08$a9780309096515 
311 08$a0309096510 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Foreword""; ""Contents""; ""Executive Summary""; ""1 Introduction""; ""2 Overview of HIVNET 012""; ""3 Study Design, Treatment Assignment, and Adherence to Study Regimens""; ""4 Efficacy and Safety""; ""5 Review of Ethical Issues""; ""6 Response to the Charge to the Committee""; ""Appendixes""; ""Appendix A Agendas of Information-Gathering Meetings""; ""Appendix B Comparisons to Other Perinatal HIV Prevention Studies Using NVP and ZDV""; ""Appendix C Committee Biographies""
330   $aMother-to-child transmission of HIV-1 afflicts hundreds of thousands of children every year, especially in parts of the world such as sub-Saharan Africa, where HIV infection is prevalent and resources are limited. This tragic reality has spurred researchers to search for an effective, safe, and inexpensive treatment that could reduce the risk of perinatal HIV transmission. The HIVNET 012 trial was designed to provide preliminary information on the comparative safety and efficacy of two relatively simple and inexpensive short courses of oral antiretroviral treatment likely to be feasible in resource-limited settings. The resulting report identified some problems with procedures and documentation, but concluded that these issues did not compromise the results of the study. However, these issues have led to public scrutiny and continued controversy. Review of the HIVNET 012 Perinatal HIV Prevention Study critically and objectively evaluates the study's design and conduct, and assesses the impact of the initial procedural issues on the validity of the overall findings and conclusions of the trial.
606   $aHIV infections$xPrevention
606   $aHIV infections$xTransmission
606   $aPerinatology
615  0$aHIV infections$xPrevention.
615  0$aHIV infections$xTransmission.
615  0$aPerinatology.
676   $a618.3
712 02$aInstitute of Medicine (U.S.).$bCommittee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910953579403321
996   $aReview of the HIVNET 012 perinatal HIV prevention study$94353781
997   $aUNINA